Search
Auplus Medical has recently announced the successful completion of a Series C funding round, securing nearly RMB 100 million. This round was led jointly by Jinan International Medical Center Industrial Development Co., Ltd. and Jinan Huaiyin District Guorong Holding Co., Ltd., with additional investment from Hillhouse Capital. The funds raised will be allocated primarily towards the research and development, mass production, and commercialization of AI-driven endovascular interventional surgical robots. The goal is to expedite the establishment of a world-class ecosystem for intelligent surgical robots. Auplus Medical, a specialist in vascular interventional surgical robots, offers products that integrate high-end manufacturing, artificial intelligence, and 5G technology, making them suitable for a wide range of interventional surgeries.
-
C114 Communication Network -
Communication Home
